Matches in SemOpenAlex for { <https://semopenalex.org/work/W2521566154> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2521566154 endingPage "5" @default.
- W2521566154 startingPage "4031" @default.
- W2521566154 abstract "In the adjuvant treatment of breast cancer, anthracycline and taxane based regimens can be used concomitantly or sequentially. The best order in the sequential regimens has yet to be well established. This study evaluated the feasibility of 4 cycles of adjuvant taxotere (100mg/m2) every 3 weeks followed by 4 cycles of doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) every 3 weeks. The primary outcome was the safety profile. Secondary outcomes were disease free survival (DFS) and overall survival (OS).This non-randomized prospective phase II study was performed at Jordan University of Science and Technology and its affiliated King Abdulla Teaching Hospital between July 2009 and August 2010. Data collection was closed on May 31th, 2015, giving a median follow up period of 62 months. The study was approved by the institutional review board and written informed consent was obtained for each patient.Fifty patients were enrolled. The median age was 53.1 years (range 34-76). One patient (2%) had stage I disease, 17 (34%) stage II, and 32 (64.0%) stage III. Forty-six patients were evaluable for efficacy analysis. The completion rate was 95.7%. No dose modifications were needed. The incidences of grade 3-4 neutropenia and febrile neutropenia were 14% and 10%. No grade 3-4 non-hematological adverse events were encountered. At a median follow up time of 62 months the OS and the DFS rates were 76.1% and 56.5%. Those for stages I and II combined were 100% and 75%.Taxotere first followed by doxorubicin-cyclophosphamide appears a feasible regimen as evidenced by an acceptable completion rate, a satisfactory safety profile, and OS and DFS rates comparable to other studies." @default.
- W2521566154 created "2016-09-30" @default.
- W2521566154 creator A5014635949 @default.
- W2521566154 creator A5056564440 @default.
- W2521566154 date "2016-01-01" @default.
- W2521566154 modified "2023-09-26" @default.
- W2521566154 title "Phase II Study of Compliance and Morbidity with 4 Cycles of Taxotere Followed by 4 of Doxorubicin-Cyclophosphamide for Adjuvant Treatment of Operable Breast Cancer Patients." @default.
- W2521566154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27644657" @default.
- W2521566154 hasPublicationYear "2016" @default.
- W2521566154 type Work @default.
- W2521566154 sameAs 2521566154 @default.
- W2521566154 citedByCount "0" @default.
- W2521566154 crossrefType "journal-article" @default.
- W2521566154 hasAuthorship W2521566154A5014635949 @default.
- W2521566154 hasAuthorship W2521566154A5056564440 @default.
- W2521566154 hasConcept C121608353 @default.
- W2521566154 hasConcept C126322002 @default.
- W2521566154 hasConcept C141071460 @default.
- W2521566154 hasConcept C197934379 @default.
- W2521566154 hasConcept C2776694085 @default.
- W2521566154 hasConcept C2776755627 @default.
- W2521566154 hasConcept C2776802502 @default.
- W2521566154 hasConcept C2777063308 @default.
- W2521566154 hasConcept C2777511904 @default.
- W2521566154 hasConcept C2778850193 @default.
- W2521566154 hasConcept C530470458 @default.
- W2521566154 hasConcept C71924100 @default.
- W2521566154 hasConceptScore W2521566154C121608353 @default.
- W2521566154 hasConceptScore W2521566154C126322002 @default.
- W2521566154 hasConceptScore W2521566154C141071460 @default.
- W2521566154 hasConceptScore W2521566154C197934379 @default.
- W2521566154 hasConceptScore W2521566154C2776694085 @default.
- W2521566154 hasConceptScore W2521566154C2776755627 @default.
- W2521566154 hasConceptScore W2521566154C2776802502 @default.
- W2521566154 hasConceptScore W2521566154C2777063308 @default.
- W2521566154 hasConceptScore W2521566154C2777511904 @default.
- W2521566154 hasConceptScore W2521566154C2778850193 @default.
- W2521566154 hasConceptScore W2521566154C530470458 @default.
- W2521566154 hasConceptScore W2521566154C71924100 @default.
- W2521566154 hasIssue "8" @default.
- W2521566154 hasLocation W25215661541 @default.
- W2521566154 hasOpenAccess W2521566154 @default.
- W2521566154 hasPrimaryLocation W25215661541 @default.
- W2521566154 hasRelatedWork W191016762 @default.
- W2521566154 hasRelatedWork W1964662020 @default.
- W2521566154 hasRelatedWork W2124452923 @default.
- W2521566154 hasRelatedWork W2298847288 @default.
- W2521566154 hasRelatedWork W2410270081 @default.
- W2521566154 hasRelatedWork W2491703090 @default.
- W2521566154 hasRelatedWork W2589321379 @default.
- W2521566154 hasRelatedWork W2695590130 @default.
- W2521566154 hasRelatedWork W4242272640 @default.
- W2521566154 hasRelatedWork W4243635078 @default.
- W2521566154 hasVolume "17" @default.
- W2521566154 isParatext "false" @default.
- W2521566154 isRetracted "false" @default.
- W2521566154 magId "2521566154" @default.
- W2521566154 workType "article" @default.